$6.74
0.59% yesterday
Nasdaq, Jun 25, 10:00 pm CET
ISIN
US5907171046
Symbol
MESO

Mesoblast Limited Sponsored ADR Share price

$6.74
-1.43 17.50% 1M
+4.58 212.04% 6M
+4.54 206.36% YTD
-0.94 12.24% 1Y
-9.62 58.80% 3Y
-4.46 39.82% 5Y
-34.30 83.58% 10Y
Nasdaq, Closing price Tue, Jun 25 2024
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Key figures

Market capitalization $773.76m
Enterprise Value $818.21m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 105.99
P/S ratio (TTM) P/S ratio 100.23
P/B ratio (TTM) P/B ratio 1.35
Sales growth (TTM) Sales growth -24.47%
Turnover (TTM) Turnover $7.72m
EBIT (operating result TTM) EBIT $-72.58m
Free cash flow (TTM) Free cash flow $-69.55m
Cash position $71.32m
EPS (TTM) EPS $-1.06
P/E ratio expected negative
P/S ratio expected 81.05
EV/Sales expected 85.71
Short interest 1.14%
Show more

Is Mesoblast Limited Sponsored ADR a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.

Mesoblast Limited Sponsored ADR Share analysis

Unlock scores for free

Analyst opinions

4 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

4x Buy
100%

Analyst opinions

4 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy
100%

Financial data from Mesoblast Limited Sponsored ADR

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Dec '23
+/-
%
7.72 7.72
2% 2%
100%
- Direct costs 28 28
6% 6%
359%
-19 -19
7% 7%
-245%
- Selling and administrative expenses 25 25
5% 5%
329%
- Research and development costs 27 27
2% 2%
352%
- -
-
-
- Depreciation and amortization - -
-
-
EBIT (operating result) EBIT -73 -73
3% 3%
-940%
Net profit -82 -82
3% 3%
-1,061%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Mesoblast Limited Sponsored ADR share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Mesoblast Limited Sponsored ADR Share News

Neutral
GlobeNewsWire
23 days ago
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.
Neutral
GlobeNewsWire
about 2 months ago
FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure
Positive
InvestorPlace
3 months ago
For bold investors, there are few opportunities as exciting as chasing 10x returns in the stock market. Make no mistake about it, the stock market offers up multiple opportunities to turn $1 into $10 quickly.
More Mesoblast Limited Sponsored ADR News

Company profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 83
Founded 2004
Website www.mesoblast.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now